--Revenue expected to be approximately $100.0 million in FY 2025, representing growth of 25%-- --Revenue expected to be approximately $26.6 million in Q4 2025, representing growth of 24%-- --2026 ...
NeuroPace, Inc., a medical device company focused on improving the lives of individuals with epilepsy, has announced that an abstract from its Post-approval Study of the RNS System will be presented ...
The company reiterated "full year 2026 revenue guidance of $98 million to $100 million," assuming "underlying core RNS growth of 20% to 22% within our current adult focal epilepsy indication and ...
NeuroPace, Inc. NPCE is well-positioned for solid growth, driven by strong RNS adoption, expanding referral networks and AI-driven innovations that enhance efficiency and utilization. The potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results